

Bevacizumab E3200

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Bevacizumab E3200

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of patients with metastatic carcinoma of the colon or rectum

Experimental Arm: Bevacizumab + FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil)

Control Arm: FOLFOX4 (oxaliplatin, folinic acid, 5-fluorouracil)

